Metric Bio’s Post

Understanding biotech means recognizing its challenges and nuances. At HiRO, we don't just advise; we integrate, becoming an extension of your team. In this video HiRO Chief Commercial Officer Wendy Mach delves deeper into how we stand beside you, not just focused on each task. 🔗 Watch the video to see Wendy articulate the HiRO difference. Learn more about "The Crucial Role of Early Engagement and Expertise in Clinical Trial Strategy Development" in this blog: https://lnkd.in/gA4Gqru6 #HiROPartnership #BeyondConsulting #TeamIntegration #BiotechInsights

Kudos to my colleagues for representing Essenvia, a #regulatory submission platform for #MedTech organizations, in its Series A financing. Essenvia helps MedTech organizations rapidly submit eSTAR, EUMDR, and IVDR, eliminate common submission errors, and maximize their device’s revenue potential. Check out more info on Essenvia and its Series A financing below. #FoleyDeals

David Li emphasizes the balance between patient impact and investor value in biotech innovation 🌟💡 #BiotechImpact #InnovationStrategy #TheBiotechStartupsPodcast

Good bye #munchen & #bioeurope2023. Food for thoughts on biotech partnering for products and projects aiming to progress medical boundaries and provide better patients' outcomes. Big or small, pre-revenue or blue-chip, acquirer or acquired, most importantly all driving healthcare for all.

Though improving diversity in #clinicaltrials is critical, it's not a simple endeavor, particularly for the small-to-mid-sized #biotech and #DTx companies. Early protocol design planning is crucial to ensure sponsors are meeting the current regulatory requirements. This may sound intimidating, however, Curavit makes it simple with our Inclusivity, #Diversity, and Equity in Action (#IDEA) Toolkit! Check out our toolkit, laid out step-by-step, with insightful expositions from Curavit's Solutions Manager, Natália Husby, in this Applied Clinical Trials Magazine article. https://lnkd.in/gg8HFRjA

As a client you can set your own expense thresholds or partially approve any amount you want within the system. Have an expense policy, yet you keep approving over the amount consistently? No problem, add a buffer to any expense within seconds.

🌍 Ready for global expansion in #orphan and #raredisease markets?   Sciensus offers an end-to-end solution for biotech firms:   1. Finding Patients: Through strong and well-established local networks, we can easily find and reach patients across the region who could benefit from your product.   2. Accessing Patients: Thanks to our expert regulatory understanding, early access opportunities, and efficient supply chain management we can ensure safe and timely product access.   3. Supporting Patients: We can provide ongoing support through Patient Support Programs, combining digital and face-to-face interventions for enhanced health outcomes. Ready to grow your business? Discover more at Sciensus. Patients. Found. https://lnkd.in/erJBT-GX #Biotech #RareDiseases #GlobalExpansion #SciensusSolutions #PatientAccess #OrphanDrugs

Put Your Company in the Best Position to get Financing at J.P. Morgan Healthcare Conference/ #BiotechShowcase2024 in January.   Put your company in the best position to get financing at the JP Morgan Healthcare Conference/Biotech Showcase week in January by determining the economic and clinical value of your asset much earlier in the investment cycle and demonstrate that value to investors, payers, patients, and providers.    Our best in class clinical/commercial assessments provide “defensible” revenue assumptions and forecasts that include today's standard of care (SOC), the emerging SOC, rigorous competitive intelligence and MD & Payer market research while leveraging Bridge’s intrinsic value driven cost model.   The investor story is amplified through the creation of a “Living Brand” that delivers your corporate & product “promise” strategically across all stakeholder communications (including investors).   The tagline in the old American Express credit card commercial featuring Carl Malden was “don’t leave home without it” and in today’s biotech financing FREEZE, the adage is “don’t come to SF in January seeking money if you don’t have your clinical & economic value story buttoned down.”    I'm Russ Belden, the founder & CEO of Bridge and we are here to put you on a path to a successful financing in January.     There is a modest window to get such work done if it’s initiated in the next few weeks. If you’ll send your availability, I’ll set up a 30-minute zoom call.    Best- Russ Belden Bridge: Founder & CEO 415-307-0774 [email protected] Bridge1.net #JPMorganchasehealthcareconference #healthcare #funding #biotech #pharma #branding

Streamlined approvals and threshold buffers reduce outside-of-policy admin. Efficient expense management in clinical research enables partial approval of expenses, aligning with the unique needs of sites, sponsors, and patients. Discover how these features can enhance your clinical trial processes: https://www.skyelarke.com/ #ExpenseManagement #ClinicalResearch #BioTech #HealthInnovation

Keep the conversation going from the #Biotech CEO Summit! One of the major takeaways is the growing importance of an Integrated Evidence Generation approach, where medical value is created faster by connecting diverse topics, fields and experiences, rather than considering them in isolation (or opposition). The art of product development is about merging perspectives of all stakeholders – patients, physicians, and payers – and combining them into an integrated research, clinical, and real world/commercial plan. Connect with our EVP of Biopharma Joris Pezzini to continue the discussion or visit our dedicated biotech page: https://lnkd.in/dVAEZRKN. We’d love to help you meet your development and funding goals!